Towards Healthcare
Tumor Fluid Biopsy Market Growth from 2025 to 2034

Tumor Fluid Biopsy Market 2025 Outlook AI, NGS & MRD Tracking Fuel Future Growth to 2034

The tumor fluid biopsy market is growing because this technique has drastically transformed the sector of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, inventing targeted therapeutic regimens, and screening for therapeutic resistance. North America is dominated due to advanced healthcare infrastructure and high adoption rates.

  • Insight Code: 5955
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

Uncover projected revenue growth and market drivers for the global tumor fluid biopsy industry from 2025 to 2034.

North America is currently leading the tumor fluid biopsy market due to advanced diagnostic technologies, significant investments in research and development.

The tumor fluid biopsy market includes seven segments such as by fluid type, by biomarker type, by technology, by cancer type, by application, by end user, and by region.

Key trends include a rise in personalized medicine and the rising prevalence of cancer.

The biopsy test cost in India varies from ₹25,000 to ₹2,50,000, depending on various parameters, from different markers screened to the laboratory tested in India.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.